FDA requires healthcare providers to report any death after COVID-19 vaccination to VAERS, even if it’s unclear whether the vaccine was the cause. Reports of death after COVID-19 vaccination are rare.Through follow-up, including medical record reviews, CDC and FDA have verified 1,328 reports of myocarditis or Learn more about myocarditis and pericarditis, including clinical considerations, after mRNA COVID-19 vaccination. Most cases have been reported after receiving Pfizer-BioNTech or Moderna, (mRNA COVID-19 vaccines) particularly in male adolescents and young adults. As of February 24, 2022, VAERS has received 2,261 preliminary reports of myocarditis or pericarditis among people ages 30 years and younger who received COVID-19 vaccines. Most patients with myocarditis or pericarditis after COVID-19 vaccination responded well to medicine and rest and felt better quickly. Myocarditis is inflammation of the heart muscle, and pericarditis is inflammation of the outer lining of the heart. Myocarditis and pericarditis after COVID-19 vaccination are rare.CDC and FDA will continue to monitor for and evaluate reports of GBS occurring after COVID-19 vaccination and will share more information as it becomes available.

Analysis found no increased risk of GBS after Pfizer-BioNTech or Moderna (mRNA COVID-19 vaccines). After the first 42 days, the rate of GBS was 11 times higher following J&J/Janssen COVID-19 vaccination. These cases have largely been reported about 2 weeks after vaccination and mostly in men, many in those ages 50 years and older.īased on the data, the rate of GBS within the first 21 days following J&J/Janssen COVID-19 vaccination was found to be 21 times higher than after Pfizer-BioNTech or Moderna (mRNA COVID-19 vaccines). After more than 18.4 million J&J/Janssen COVID-19 vaccine doses administered, there have been around 303 preliminary reports of GBS identified in VAERS as of February 24, 2022. Most people fully recover from GBS, but some have permanent nerve damage. GBS is a rare disorder where the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis.

Guillain-Barré Syndrome (GBS) in people who have received the J&J/Janssen COVID-19 vaccine is rare.

Based on available data, there is not an increased risk for TTS after mRNA COVID-19 vaccination.

To date, three confirmed cases of TTS following mRNA COVID-19 vaccination (Moderna) have been reported to VAERS after more than 532 million doses of mRNA COVID-19 vaccines administered in the United States.

There are other COVID-19 vaccine options available for which this risk has not been seen.

Women ages 30-49 years, especially, should be aware of the increased risk of this rare adverse event. CDC and FDA identified 57 confirmed reports of people who got the J&J/Janssen COVID-19 vaccine and later developed TTS.ĬDC has also identified nine deaths that have been caused by or were directly attributed to TTS following J&J/Janssen COVID-19 vaccination. As of February 24, 2022, more than 18.4 million doses of the J&J/Janssen COVID-19 vaccine have been given in the United States. Thrombosis with thrombocytopenia syndrome (TTS) after Johnson & Johnson’s Janssen (J&J/Janssen) COVID-19 vaccination is rare. TTS is a rare but serious adverse event that causes blood clots in large blood vessels and low platelets (blood cells that help form clots).Learn more about COVID-19 vaccines and allergic reactions, including anaphylaxis. If it happens, healthcare providers can effectively and immediately treat the reaction. Anaphylaxis, a severe type of allergic reaction, can occur after any kind of vaccination. Anaphylaxis after COVID-19 vaccination is rare and has occurred in approximately 5 people per one million vaccinated in the United States.CDC is providing timely updates on the following serious adverse events of interest:

A negative blood type and covid